News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ERYtech Pharma's Sickle Cell Treatment Receives Positive Opinion for Orphan Drug Designation from the European Medicines Agency


6/13/2012 10:24:22 AM

LYON, France--(BUSINESS WIRE)--ERYTECH Pharma, a late stage biopharmaceuticals company focused on orphan oncology and rare diseases, announces that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) adopted a positive opinion to grant Orphan Drug Designation (ODD) to its investigational product ENHOXY® for sickle cell disease.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES